Navigation Links
Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
Date:7/21/2011

ALLEGAN, Mich., July 21, 2011 /PRNewswire/ -- The Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex gum USP, 2 mg and 4 mg cinnamon flavor.

The product will be marketed under store brand labels and is comparable to GlaxoSmithKline's Nicorette® Cinnamon Surge™ coated gum, which is a stop smoking aid. "This approval of coated cinnamon nicotine gum extends our leading store brand position. The expanded range of smoking cessation products also includes coated mint-flavored gum, coated fruit wave, uncoated gum and lozenges," said Joseph C. Papa, Perrigo's Chairman and Chief Executive Officer. Nicorette® Cinnamon Surge™ gum is selling at an annual rate estimated at over $40 million at all retail outlets.  First shipments are expected to ship this fall.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).  

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actua
'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 /PRNewswire/ ... period for commercially-insured patients with Type 2 diabetes, ... shown to improve health outcomes and can lead ... studies presented at the International Society for Pharmacoeconomics ... The two studies, sponsored by Valeritas, ...
(Date:5/22/2013)... 2013   Life Line Screening  (LLS), a ... the creation of a unique partnership with MCM ... MCM is a population health management organization. LLS will ... clients. These important expanded services will help MCM and ... prevention reduces cost of care when individuals are able ...
(Date:5/22/2013)... May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the following conferences. ... Presentation date: Wednesday May 29, 2013 , Presentation time: ... Healthcare Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of ...
Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... MOUNTAIN VIEW, Calif. , Jan. 28 Omnicell, Inc. (Nasdaq: ... facilities, today announced results for its fourth quarter and year ended ... fourth quarter of 2009 was $54.7 million , up $0.7 ... $7.4 million or 11.9% from the fourth quarter of 2008. ...
... , SAN DIEGO , Jan. 28 ... Phase II clinical trial evaluating CTS-1027 in combination with pegylated ... activity, safety and tolerability of the triple combination will be ... is a significant unmet medical need in HCV patients who ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
(Date:5/22/2013)... People in the United States have been ... shortages. In much of the world, water shortages are normal ... Kleyne. She warns against taking water for granted and provides ... so easily in the United States. , Sharon Kleyne is ... show, heard live or by podcast on World Talk Radio, ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Bodybuilding.com ... Memorial Day (May 27, 2013) Bodybuilding.com will be donating $1 ... the amount. , “We are extremely grateful for the ... Armed Forces,” said Ryan DeLuca, CEO and founder of Bodybuilding.com. ... who have sacrificed so much. Hire Heroes USA is an ...
(Date:5/22/2013)... Twenty student-led startup companies at Arizona ... an intensive startup accelerator designed to help them execute ... create local jobs as part of ASU’s Edson ... initiative offers approximately 20 student teams up to $20,000 ... to launch their for-profit, more-than-profit or nonprofit ventures. The ...
(Date:5/22/2013)... Researchers in genomic health disparities from the University of ... School of Medicine have teamed up to hold the ... Health Disparities in Genomic Medicine." The theme of ... business and government to reduce these disparities. , Despite ... States, individuals within underserved groups continue to be more ...
(Date:5/22/2013)... Johns Hopkins researchers report that hospitals may be ... are complicated by preventable bloodstream infections contracted in ... new study, reported online in the American ... that an ICU patient who develops an avoidable ... times more to care for than a similar ...
Breaking Medicine News(10 mins):Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:In the Spirit of Memorial Day, Bodybuilding.com is Donating a Portion of Their Sales to Hire Heroes 2Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 2Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 3Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 4Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 5Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 6Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 7Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 8Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 9Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4
... have said that sleep would probably help the human brain ... facts.// ,It was reported that previous studies had ... steps of learning to tap numeric sequences on a keyboard. ... declarative memory like those used for recalling the facts for ...
... (MIMS) is planning to launch a chain of satellite hospitals ... of non-resident Indian (NRI) doctors residing in Gulf Cooperation Council ... Kottakal in Malappuram district of the state for the purpose, ... ,MIMS chairman Azad Moopen told the newspaper that the ...
... Zealand Food Safety Authority (NZFSA) has warned people against ... bags are clearly labelled as requiring to be cooked ... is known to sometimes carry norovirus, which causes a ... Korean oysters are packed frozen in 1kg bags and ...
... at the Institute Of Cancer Research have discovered a new ... disease.// ,It is found that if a person ... diagnosed with breast cancer doubles. This would serve as a ... of cancer and thereby help treat and prevent the disease. ...
... differently in the same organs of males and females ... sheds light on why the same disease often strikes ... respond differently to the same drug. ,"We ... vary in their relationship to different diseases," explained Xia ...
... begin before the age of 14 years are not only ... from alcohol until they're 21//, but they also tend to ... with alcohol throughout their lives. ,The study's lead ... of Public Health's Youth Alcohol Prevention Centre said that while ...
Cached Medicine News:Health News:Sleep Essential For A Strong Memory 2Health News:Same Genes Act Differently in Males and Females 2Health News:Same Genes Act Differently in Males and Females 3Health News:Alcoholism & Dependence Seen More Commonly In Early Alcohol Drinkers 2
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: